Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interleukin-11.

A J Dorner1, S J Goldman, J C Keith

  • 1Department of Preclinical Research and Development, Genetics Institute Inc., Cambridge, Massachusetts, USA.

Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|November 23, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characterization of Circulating Tumor DNA for Genetic Assessment of solid Tumors.

Clinical pharmacology and therapeutics·2015
Same author

Global analysis of nuclear receptor expression and dysregulation in human osteoarthritic articular cartilage: reduced LXR signaling contributes to catabolic metabolism typical of osteoarthritis.

Osteoarthritis and cartilage·2009
Same author

In vitro allergen challenge of peripheral blood induces differential gene expression in mononuclear cells of asthmatic patients: inhibition of cytosolic phospholipase A2alpha overcomes the asthma-associated response.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2008
Same author

Activation-induced cellular accumulation of histamine in immature but not mature murine mast cells.

Cellular and molecular life sciences : CMLS·2008
Same author

Utility of animal models for identification of potential therapeutics for rheumatoid arthritis.

Annals of the rheumatic diseases·2007
Same author

Experience with voluntary and required genomic data submissions to the FDA: summary report from track 1 of the third FDA-DIA-PWG-PhRMA-BIO pharmacogenomics workshop.

The pharmacogenomics journal·2006
Same journal

Ustekinumab Biosimilars versus Reference Ustekinumab for Moderate-to-Severe Plaque Psoriasis: A Pre-switch Systematic Review and Meta-analysis.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Correction: Mirikizumab as Induction and Maintenance Therapy in Chinese Patients with Ulcerative Colitis: A Subpopulation Analysis of the Randomized, Global Phase 3 LUCENT-1 and LUCENT-2 Trials.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Gene Therapy Strategies for Uveal Melanoma: Adeno-associated Virus Delivery Challenges and Translational Opportunities.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Review of Quality Attributes and Analytical Methods Used for Comparative Analytical Assessment of Monoclonal Antibodies as Part of Successful Biosimilar Approvals in the United States and European Union.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Impact of Repeated Antigen Exposure on Humoral Tolerance: Antidrug Antibodies After Single-Dose Versus Multi-dose Adalimumab.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

An Overview and Trend Analysis of Biosimilar Approvals in China.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
See all related articles

Interleukin-11 (IL-11) stimulates blood cell growth and protects against chemotherapy side effects like low platelets and mucositis. This cytokine also reduces inflammation and tissue damage in various conditions.

Area of Science:

  • Biochemistry
  • Immunology
  • Hematology

Background:

  • Interleukin-11 (IL-11) is a cytokine with diverse cellular interactions.
  • Recombinant human IL-11 (rhIL-11; oprelvekin) is a modified form used therapeutically.
  • IL-11 plays roles in hematopoiesis, inflammation, and tissue repair.

Purpose of the Study:

  • To evaluate the therapeutic potential of rhIL-11.
  • To investigate rhIL-11's effects on hematopoiesis, gastrointestinal damage, and inflammation.
  • To explore rhIL-11's efficacy in preclinical models and clinical trials.

Main Methods:

  • In vitro studies on progenitor cell growth.
  • In vivo animal models for chemotherapy-induced thrombocytopenia, mucositis, colitis, endotoxemia, and sepsis.

Related Experiment Videos

  • Clinical trials for chemotherapy-induced thrombocytopenia and mucositis.
  • Analysis of cytokine production, hypotension, and survival rates.

    • Main Results:

    • rhIL-11 stimulates megakaryocytopoiesis and thrombopoiesis, reducing chemotherapy-induced thrombocytopenia in clinical trials.
    • rhIL-11 protects against gastrointestinal mucosal damage, reducing mucositis severity and improving survival in animal models.
    • rhIL-11 reduces pro-inflammatory mediators, alleviates inflammatory bowel disease signs, and improves survival in sepsis models.
    • rhIL-11 induces acute phase reactants and tissue repair factors like TIMP-1.

    Conclusions:

    • rhIL-11 demonstrates significant therapeutic benefits in preventing thrombocytopenia and mucositis.
    • rhIL-11 exhibits potent anti-inflammatory and tissue-protective properties.
    • rhIL-11 is a promising therapeutic agent for inflammatory conditions and chemotherapy complications.